DXCM vs PODD
DXCM: Dexcom is a leader in continuous glucose monitoring (CGM) technology, providing essential real-time health data for diabetes management and metabolic health. PODD: Insulet Corporation provides tubeless, wearable insulin management technology that simplifies diabetes care for millions of patients worldwide.
Side-by-side fundamentals
| Metric | DXCM | PODD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $71.43 | $158.93 | |
| Market cap as of 2026-07-23 | $28.8B | $11.3B | |
| P/E as of 2026-07-23 | 31.00 | 37.44 | DXCM lower |
| PEG as of 2026-07-23 | 1.26 | 1.23 | PODD lower |
| Net margin as of 2026-07-23 | +19.3% | +10.4% | DXCM higher |
| Gross margin as of 2026-07-23 | +63.4% | +71.0% | PODD higher |
| Operating margin as of 2026-07-23 | +21.4% | +14.6% | DXCM higher |
| ROE as of 2026-07-23 | +33.8% | +17.4% | DXCM higher |
| ROA as of 2026-07-23 | +13.4% | +7.5% | DXCM higher |
| Debt / equity as of 2026-07-23 | 0.44 | 0.63 | DXCM lower |
| Revenue growth (YoY) as of 2026-07-23 | +16.1% | +31.9% | PODD higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | +27.5% | PODD higher |
| Beta as of 2026-07-23 | 1.42 | 1.10 | |
| 1-year return as of 2026-07-22 close | -11.0% | -44.3% | DXCM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.